Shopping Cart 0
Cart Subtotal
USD 0

Dermatomyositis-Pipeline Review, H1 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Dermatomyositis-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dermatomyositis-Pipeline Review, H1 2017, provides an overview of the Dermatomyositis (Musculoskeletal Disorders) pipeline landscape.

Dermatomyositis is a rare inflammatory disease which is characterized by chronic muscle inflammation accompanied by muscle weakness. Symptoms of dermatomyositis include a distinctive skin rash, muscle weakness, and inflammatory myopathy, or inflamed muscles. Risk factors include age and gender. Treatment includes corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dermatomyositis-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Dermatomyositis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dermatomyositis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Dermatomyositis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 6, 3 and 2 respectively.

Dermatomyositis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Dermatomyositis (Musculoskeletal Disorders).

The pipeline guide reviews pipeline therapeutics for Dermatomyositis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Dermatomyositis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Dermatomyositis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Dermatomyositis (Musculoskeletal Disorders)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Dermatomyositis (Musculoskeletal Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Dermatomyositis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Dermatomyositis-Overview

Dermatomyositis-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Dermatomyositis-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Dermatomyositis-Companies Involved in Therapeutics Development

Eli Lilly and Company

F. Hoffmann-La Roche Ltd

Hope Pharmaceuticals Inc

Idera Pharmaceuticals Inc

KPI Therapeutics Inc

Marathon Pharmaceuticals LLC

MedImmune LLC

Neovacs SA

Novartis AG

Octapharma AG

Pfizer Inc

Dermatomyositis-Drug Profiles

anabasum-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

baricitinib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dalazatide-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

immune globulin (human)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMO-8400-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MEDI-7734-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MP-117-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

siponimod-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sodium thiosulfate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tocilizumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tofacitinib citrate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target IFN-Alpha for Metabolic Disorders, Immunology, Infectious Diseases and Musculoskeletal Disorders-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Dermatomyositis-Dormant Projects

Dermatomyositis-Product Development Milestones

Featured News & Press Releases

May 17, 2017: FDA Grants Octapharma USA Orphan Drug Designation for Octagam 10% for the Treatment of Dermatomyositis

May 11, 2017: Corbus Pharmaceuticals Announces Last Subject Enrolled in Phase 2 Study of Anabasum for the Treatment of Skin-Predominant Dermatomyositis

May 04, 2017: Neovacs to present clinical development update on IFNalpha Kinoid in dermatomyosis

Mar 09, 2017: Neovacs to present IFNalpha Kinoid technology and its clinical outlooks at upcoming Keystone Symposia Conference

Feb 09, 2017: Neovacs Issued New Broad Patent in China for IFNa Kinoid

Nov 29, 2016: Corbus Pharmaceuticals Commences One-Year Open-Label Extension to its Ongoing Phase 2 Study of Resunab (JBT-101) for Skin-Predominant Dermatomyositis

Sep 28, 2016: Corbus Announces Data on Effects of Resunab (JBT-101) in a Clinical Research Model of Resolution of Inflammation

Nov 09, 2015: Idera Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of IMO-8400 in Patients with Dermatomyositis

Oct 13, 2015: Corbus Pharmaceuticals to Present at the 14th Annual BIO Investor Forum

Aug 06, 2015: Corbus Pharmaceuticals to Present at the Canaccord Genuity Growth Conference on August 13, 2015

Jul 13, 2015: Corbus Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of Resunab for the Treatment of Dermatomyositis

Jun 16, 2015: Neovacs initiates clinical program in Dermatomyositis

Jun 16, 2015: Neovacs initiates clinical program in Dermatomyositis

Jun 05, 2015: Corbus Pharmaceuticals Expands Clinical Development of Resunab With a Phase 2 Trial for the Treatment of Rare Disease Dermatomyositis

May 13, 2015: Neovacs granted 1.8 million euros in research tax credit

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Dermatomyositis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017


List Of Table

List of Tables

Number of Products under Development for Dermatomyositis, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Dermatomyositis-Pipeline by Eli Lilly and Company, H1 2017

Dermatomyositis-Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Dermatomyositis-Pipeline by Hope Pharmaceuticals Inc, H1 2017

Dermatomyositis-Pipeline by Idera Pharmaceuticals Inc, H1 2017

Dermatomyositis-Pipeline by KPI Therapeutics Inc, H1 2017

Dermatomyositis-Pipeline by Marathon Pharmaceuticals LLC, H1 2017

Dermatomyositis-Pipeline by MedImmune LLC, H1 2017

Dermatomyositis-Pipeline by Neovacs SA, H1 2017

Dermatomyositis-Pipeline by Novartis AG, H1 2017

Dermatomyositis-Pipeline by Octapharma AG, H1 2017

Dermatomyositis-Pipeline by Pfizer Inc, H1 2017

Dermatomyositis-Dormant Projects, H1 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Hope Pharmaceuticals Inc, Idera Pharmaceuticals Inc, KPI Therapeutics Inc, Marathon Pharmaceuticals LLC, MedImmune LLC, Neovacs SA, Novartis AG, Octapharma AG, Pfizer Inc

Dermatomyositis-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dermatomyositis-Pipeline Review, H1 2017, provides an overview of the Dermatomyositis (Musculoskeletal Disorders) pipeline landscape.

Dermatomyositis is a rare inflammatory disease which is characterized by chronic muscle inflammation accompanied by muscle weakness. Symptoms of dermatomyositis include a distinctive skin rash, muscle weakness, and inflammatory myopathy, or inflamed muscles. Risk factors include age and gender. Treatment includes corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dermatomyositis-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Dermatomyositis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dermatomyositis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Dermatomyositis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 6, 3 and 2 respectively.

Dermatomyositis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Dermatomyositis (Musculoskeletal Disorders).

The pipeline guide reviews pipeline therapeutics for Dermatomyositis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Dermatomyositis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Dermatomyositis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Dermatomyositis (Musculoskeletal Disorders)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Dermatomyositis (Musculoskeletal Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Dermatomyositis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Dermatomyositis-Overview

Dermatomyositis-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Dermatomyositis-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Dermatomyositis-Companies Involved in Therapeutics Development

Eli Lilly and Company

F. Hoffmann-La Roche Ltd

Hope Pharmaceuticals Inc

Idera Pharmaceuticals Inc

KPI Therapeutics Inc

Marathon Pharmaceuticals LLC

MedImmune LLC

Neovacs SA

Novartis AG

Octapharma AG

Pfizer Inc

Dermatomyositis-Drug Profiles

anabasum-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

baricitinib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dalazatide-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

immune globulin (human)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMO-8400-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MEDI-7734-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MP-117-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

siponimod-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sodium thiosulfate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tocilizumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tofacitinib citrate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target IFN-Alpha for Metabolic Disorders, Immunology, Infectious Diseases and Musculoskeletal Disorders-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Dermatomyositis-Dormant Projects

Dermatomyositis-Product Development Milestones

Featured News & Press Releases

May 17, 2017: FDA Grants Octapharma USA Orphan Drug Designation for Octagam 10% for the Treatment of Dermatomyositis

May 11, 2017: Corbus Pharmaceuticals Announces Last Subject Enrolled in Phase 2 Study of Anabasum for the Treatment of Skin-Predominant Dermatomyositis

May 04, 2017: Neovacs to present clinical development update on IFNalpha Kinoid in dermatomyosis

Mar 09, 2017: Neovacs to present IFNalpha Kinoid technology and its clinical outlooks at upcoming Keystone Symposia Conference

Feb 09, 2017: Neovacs Issued New Broad Patent in China for IFNa Kinoid

Nov 29, 2016: Corbus Pharmaceuticals Commences One-Year Open-Label Extension to its Ongoing Phase 2 Study of Resunab (JBT-101) for Skin-Predominant Dermatomyositis

Sep 28, 2016: Corbus Announces Data on Effects of Resunab (JBT-101) in a Clinical Research Model of Resolution of Inflammation

Nov 09, 2015: Idera Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of IMO-8400 in Patients with Dermatomyositis

Oct 13, 2015: Corbus Pharmaceuticals to Present at the 14th Annual BIO Investor Forum

Aug 06, 2015: Corbus Pharmaceuticals to Present at the Canaccord Genuity Growth Conference on August 13, 2015

Jul 13, 2015: Corbus Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of Resunab for the Treatment of Dermatomyositis

Jun 16, 2015: Neovacs initiates clinical program in Dermatomyositis

Jun 16, 2015: Neovacs initiates clinical program in Dermatomyositis

Jun 05, 2015: Corbus Pharmaceuticals Expands Clinical Development of Resunab With a Phase 2 Trial for the Treatment of Rare Disease Dermatomyositis

May 13, 2015: Neovacs granted 1.8 million euros in research tax credit

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Dermatomyositis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017


List Of Table

List of Tables

Number of Products under Development for Dermatomyositis, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Dermatomyositis-Pipeline by Eli Lilly and Company, H1 2017

Dermatomyositis-Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Dermatomyositis-Pipeline by Hope Pharmaceuticals Inc, H1 2017

Dermatomyositis-Pipeline by Idera Pharmaceuticals Inc, H1 2017

Dermatomyositis-Pipeline by KPI Therapeutics Inc, H1 2017

Dermatomyositis-Pipeline by Marathon Pharmaceuticals LLC, H1 2017

Dermatomyositis-Pipeline by MedImmune LLC, H1 2017

Dermatomyositis-Pipeline by Neovacs SA, H1 2017

Dermatomyositis-Pipeline by Novartis AG, H1 2017

Dermatomyositis-Pipeline by Octapharma AG, H1 2017

Dermatomyositis-Pipeline by Pfizer Inc, H1 2017

Dermatomyositis-Dormant Projects, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Companies

Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Hope Pharmaceuticals Inc, Idera Pharmaceuticals Inc, KPI Therapeutics Inc, Marathon Pharmaceuticals LLC, MedImmune LLC, Neovacs SA, Novartis AG, Octapharma AG, Pfizer Inc